Literature DB >> 15095235

Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.

Martin Rodriguez1, Costi D Sifri, Jay A Fishman.   

Abstract

Trimethoprim-sulfamethoxazole is the preferred agent for prophylaxis against Pneumocystis jiroveci pneumonia. Alternative agents are used in treating patients who do not tolerate this medication. We report 2 cases of prophylaxis failure in patients receiving low-dose atovaquone. We discuss the use of atovaquone as an alternative agent for prophylaxis in transplant recipients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15095235     DOI： 10.1086/383150

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  5 in total

1.  The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Authors:  K M Williams; K W Ahn; M Chen; M D Aljurf; A L Agwu; A R Chen; T J Walsh; P Szabolcs; M J Boeckh; J J Auletta; C A Lindemans; J Zanis-Neto; M Malvezzi; J Lister; J S de Toledo Codina; K Sackey; J L H Chakrabarty; P Ljungman; J R Wingard; M D Seftel; S Seo; G A Hale; B Wirk; M S Smith; B N Savani; H M Lazarus; D I Marks; C Ustun; H Abdel-Azim; C C Dvorak; J Szer; J Storek; A Yong; M R Riches
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

2.  Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials.

Authors:  Jennifer M Reinhart; Alison Motsinger-Reif; Allison Dickey; Steven Yale; Lauren A Trepanier
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

3.  RNA expression profiling in sulfamethoxazole-treated patients with a range of in vitro lymphocyte cytotoxicity phenotypes.

Authors:  Jennifer M Reinhart; Warren Rose; Daniel J Panyard; Michael A Newton; Tyler K Liebenstein; Jeremiah Yee; Lauren A Trepanier
Journal:  Pharmacol Res Perspect       Date:  2018-03-02

4.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).

Authors:  Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild
Journal:  Ann Hematol       Date:  2021-04-13       Impact factor: 3.673

5.  Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids.

Authors:  Sadao Jinno; Kengo Akashi; Akira Onishi; Yoko Nose; Mai Yamashita; Jun Saegusa
Journal:  Rheumatol Int       Date:  2021-07-14       Impact factor: 3.580
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.